On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage points to growth.
The Swiss pharma giant reported adjusted EPS of $2.06, up from $1.74 a year ago and beating the consensus of $1.96
Core operating profit for the third quarter grew to $5.15 billion from $4.41 billion the year prior.
Novartis generated $6 billion in free cash flow for the third quarter, up 18% year-over-year.
"All key growth drivers contributed to the momentum. We achieved important indications expansions for Kisqali in early breast cancer and Fabhalta in IgA nephropathy, and we completed our PSMAfore filing for Pluvicto in the US. With the momentum in our business and pipeline, we were able to once again upgrade our full-year guidance and remain highly confident in our mid-term outlook," said CEO Vas Narasimhan.
Quarterly Cosentyx sales gained 27% to $1.69 billion, driven by recent launches (including the HS indication and the IV formulation in the US) and volume growth in core indications.
Heart failure drug Entresto sales increased 26% to $1.87 billion, a demand-led growth. The drug has increased penetration in the U.S. and Europe following guideline-directed medical therapy for heart failure and in China with increased penetration in hypertension.
Multiple sclerosis drug Kesimpta sales reached $838 million, up +28%, reflecting increased demand for a high-efficacy product with convenient self-administered dosing.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a "high teens" percentage, compared with previous guidance of a "mid-to-high teens" percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Price Action: NVS stock is down 3.29% at $111.82 during the premarket session at the last check on Tuesday.
週二，諾華製藥（NYSE:NVS）報告第三季度銷售額爲128.23億美元，同比增長9%（按恒定貨幣計算增長10%），超過了127.6億美元的市場共識。成交量爲增長做出了12個百分點的貢獻。
這家瑞士製藥巨頭報告調整後每股收益爲2.06美元，高於去年的1.74美元，並超出了1.96美元的市場共識
第三季度核心營業利潤從上一年的44.1億美元增長到51.5億美元。
諾華製藥第三季度自由現金流達到了60億美元，同比增長18%。
「所有主要增長驅動因素都爲勢頭做出了貢獻。我們在早期乳腺癌和IgA腎病的Kisqali獲得了重要的適應症擴展，併爲美國的Pluvicto提交了PSMAfore的申請。憑藉我們的業務和研發管線的動力，我們再次調升了全年指引，並對中期前景充滿信心，」首席執行官Vas Narasimhan表示。
季度Cosentyx銷售額增長27%至16.9億美元，受到最近推出的產品（包括在美國的HS適應症和靜脈注射製劑）以及核心適應症的成交量增長的推動。
心力衰竭藥物Entresto的銷售額增長了26%至18.7億美元，需求驅動增長。該藥物在美國和歐洲在心力衰竭指導性醫療治療後的滲透率增加，並在中國的高血壓患者中的滲透率也有所提高。
多發性硬化症藥物Kesimpta銷售額達到83800萬美元，增長28%，反映出對一種具有方便自行注射劑量且高效的產品需求增加。
指引：諾華製藥今年再次上調其2024財年全年指引。
諾華製藥在一份聲明中表示，預計全年核心營業利潤將增長高兩位數百分比，相比之前的指引爲中至上個兩位數百分比。
諾華製藥預測全年銷售額增長低兩位數百分比，此前指導爲高個位到低兩位數百分比的增長。
股價走勢：NVS的股票在週二盤前交易中下跌3.29%，報111.82美元。
